Seeing Is Believing
BMRN is currently covered by 27 analysts with an average price target of $111.7. This is a potential upside of $27.11 (32.05%) from yesterday's end of day stock price of $84.59.
Biomarin Pharmaceutical's activity chart (see below) currently has 394 price targets and 353 ratings on display. The stock rating distribution of BMRN is 72.63% BUY and 27.37% HOLD.
Analysts average stock forecasts to be materialized ratio is 54.5% with an average time for these price targets to be met of 378.21 days.
Highest price target for BMRN is $170, Lowest price target is $70, average price target is $111.7.
Most recent stock forecast was given by MOHIT BANSAL from WELLS FARGO on 27-Jun-2024.
BioMarin Pharmaceutical . is a biotechnology company that specializes in the development and commercialization of therapies for rare and life-threatening diseases. The company’s main focus is on the development of therapies for patients with genetic disorders.
BioMarin’s commercial products include Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, and Aldurazyme, which are used for the treatment of various rare diseases such as mucopolysaccharidosis, phenylketonuria, and ceroid lipofuscinosis.
The company is also developing gene therapies for hemophilia A, Hereditary Angioedema, and primary hyperoxaluria.
BioMarin has license and collaboration agreements with other pharmaceutical companies, such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners., and Asubio Pharma.
BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.
Currently out of the existing stock ratings of BMRN, 69 are a BUY (72.63%), 26 are a HOLD (27.37%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
115
$30.91 (36.76%)
110
29 days ago
4/7 (57.14%)
$31.5 (37.72%)
179
Buy
72
$-12.09 (-14.38%)
104
2 months 9 days ago
1/5 (20%)
$-5.56 (-7.17%)
415
Buy
113
$28.91 (34.38%)
2 months 12 days ago
5/13 (38.46%)
$33.35 (41.87%)
925
Hold
89
$4.91 (5.84%)
91
3 months ago
2/7 (28.57%)
$8.09 (10.00%)
33
Buy
112
$27.91 (33.19%)
117
3 months ago
13/18 (72.22%)
$31.09 (38.43%)
250
What is BMRN (Biomarin Pharmaceutical) average time for price targets to be met?
Which analyst has the current highest performing score on BMRN (Biomarin Pharmaceutical) with a proven track record?
Which analyst has the most public recommendations on BMRN (Biomarin Pharmaceutical)?
Which analyst is the currently most bullish on BMRN (Biomarin Pharmaceutical)?
Which analyst is the currently most reserved on BMRN (Biomarin Pharmaceutical)?